Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 47, Issue 2

Issues

Age and hormone replacement therapy as factors influencing androgen levels in the postmenopausal female

Iaisha Ali / Tim James
  • 2Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS Trust, Oxford, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Niki Meston
  • 3Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS Trust, Oxford, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Fenella Wojnarowska / Brian Shine
  • 5Department of Clinical Biochemistry, John Radcliffe Hospital, Oxford Radcliffe Hospitals NHS Trust, Oxford, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar

Abstract

Background: The changes in androgen levels after the menopause and the effects of hormone replacement therapy (HRT) itself and the mode of HRT have not been established. The objectives of this study were to document the effect of age on androgen levels in a normal population of postmenopausal women and to investigate the effect of oral or transdermal HRT on androgen, oestradiol and sex hormone binding globulin (SHBG) values.

Methods: A cross-sectional study was conducted on 182 postmenopausal females aged 45–100 years, randomly recruited from the community. Serum levels of dehydroepiandrosterone sulphate (DHEAS), androstenedione, testosterone, free androgen index (FAI) and SHBG in a reference group of women, subdivided by age, menopausal status, HRT replacement and mode of HRT replacement.

Results: Age was a significant factor affecting androstenedione (<55, ≥55 years) and DHEAS (<65, ≥65 years). HRT status was found to influence values for androstenedione, SHBG and FAI. Neither HRT nor age significantly influenced testosterone.

Conclusions: The observations suggest the need to provide age-specific reference intervals for androstenedione and DHEAS but not for testosterone and SHBG. The significant effect of HRT treatment would also suggest a need for treatment associated reference intervals for androstenedione, SHBG and FAI. Suggested reference intervals for each of these partitioned groups are presented.

Clin Chem Lab Med 2009;47:202–7.

Keywords: androgen; hormone replacement therapy; postmenopausal

About the article

Corresponding author: Tim James, PhD, Clinical Biochemistry, John Radcliffe Hospital, Oxford, OX3 9DU, UK Phone: +44-1865-220460, Fax: +44-1865-220348,


Received: 2008-08-14

Accepted: 2008-11-21

Published in Print: 2009-02-01


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 47, Issue 2, Pages 202–207, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2009.049.

Export Citation

©2009 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
P. Trimpou, A. Lindahl, G. Lindstedt, G. Olerod, L. Wilhelmsen, and K. Landin-Wilhelmsen
European Journal of Endocrinology, 2012, Volume 166, Number 5, Page 887

Comments (0)

Please log in or register to comment.
Log in